Clinical Trial

A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3814916 in healthy male and female trial participants.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-29
notable Primary completion pushed: 2027-02-15 -> 2027-07-12 2026-04-03
minor Completion pushed: 2027-02-15 -> 2027-07-12 2026-04-03
Trial Details
NCT Number NCT07486115
Lead Sponsor Boehringer Ingelheim
Conditions Healthy
Enrollment 136 participants
Start Date 2026-05-20
Primary Completion 2027-07-12 (estimated)
Study Completion 2027-07-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-28